Palonosetron
Palonosetron is a second-generation 5-HT3 receptor antagonist used to prevent nausea and vomiting associated with cancer chemotherapy and surgery. It has a high binding affinity for the 5-HT3 receptor and a prolonged half-life of approximately 40 hours, making it highly effective for both acute and delayed phases of chemotherapy-induced emesis.
Dosage by Body Weight
For CINV in adults: A single intravenous dose of 0.25 mg administered 30 minutes before chemotherapy, or a single oral capsule of 0.5 mg administered 1 hour before chemotherapy. For pediatric patients (1 month to 17 years), the recommended dose is 20 mcg/kg administered intravenously.
- Body Weight
- Below 5 kg
- Dose
- 20 mcg/kg (0.02 mg/kg)
- Frequency
- Single dose before chemotherapy
- Tracking Notes
- Safety and efficacy in infants under 1 month of age have not been established. Use only under strict medical supervision.
- Body Weight
- 5-7 kg
- Dose
- 100 mcg to 140 mcg (0.1 mg to 0.14 mg)
- Frequency
- Single dose
- Tracking Notes
- Administer intravenously over 30 seconds, approximately 30 minutes prior to the start of chemotherapy.
- Body Weight
- 8-10 kg
- Dose
- 160 mcg to 200 mcg (0.16 mg to 0.2 mg)
- Frequency
- Single dose
- Tracking Notes
- Administer intravenously over 30 seconds, approximately 30 minutes prior to the start of chemotherapy.
- Body Weight
- 11-15 kg
- Dose
- 220 mcg to 300 mcg (0.22 mg to 0.3 mg)
- Frequency
- Single dose
- Tracking Notes
- Administer intravenously over 30 seconds, approximately 30 minutes prior to the start of chemotherapy.
- Body Weight
- 16-20 kg
- Dose
- 320 mcg to 400 mcg (0.32 mg to 0.4 mg)
- Frequency
- Single dose
- Tracking Notes
- Administer intravenously over 30 seconds, approximately 30 minutes prior to the start of chemotherapy.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | 20 mcg/kg (0.02 mg/kg) | Single dose before chemotherapy | Safety and efficacy in infants under 1 month of age have not been established. Use only under strict medical supervision. |
| 5-7 kg | 100 mcg to 140 mcg (0.1 mg to 0.14 mg) | Single dose | Administer intravenously over 30 seconds, approximately 30 minutes prior to the start of chemotherapy. |
| 8-10 kg | 160 mcg to 200 mcg (0.16 mg to 0.2 mg) | Single dose | Administer intravenously over 30 seconds, approximately 30 minutes prior to the start of chemotherapy. |
| 11-15 kg | 220 mcg to 300 mcg (0.22 mg to 0.3 mg) | Single dose | Administer intravenously over 30 seconds, approximately 30 minutes prior to the start of chemotherapy. |
| 16-20 kg | 320 mcg to 400 mcg (0.32 mg to 0.4 mg) | Single dose | Administer intravenously over 30 seconds, approximately 30 minutes prior to the start of chemotherapy. |
Formulation
Purpose
Prevention of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).
Generic Name
PalonosetronBranded Drug Names
Palonosetron is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.